Bladder cancer (BC) is a heterogeneous disease from a molecular, morphological, and
clinical standpoint. HER2 is a known oncogene involved in bladder carcinogenesis …

Non-muscle invasive bladder cancer (NMIBC) still represents a challenge in decision-
making and clinical management since prognostic and predictive biomarkers of response to …

Background Solanum nigrum L. decoction has been used as a folklore medicine in China to
prevent the postoperative recurrence of bladder cancer (BC). However, there are no …

INTRODUCTION: Gene expression analyses have identified similarities between bladder
and breast cancer, where clinical risk stratification is based on Her2, ESR1, PGR and Ki67 …

Background To study the expression pattern, localisation and potential clinical significance
of aquaporin water channels (AQP) both in prostate cancer (PC) cell lines and in benign and …

Although human epidermal growth factor receptor 2 (HER2) plays a prognostic and
predictive role in breast and gastric cancer, its function in bladder cancer (BC) is still …

Introduction Molecular markers associated with breast cancer are assumed to be associated
with outcome in non-muscle-invasive bladder cancer (NMIBC). Materials and methods We …

Background B7-H3 has been implicated in clinical pathological features and prognosis
across various cancer types, suggesting its potential as a cancer biomarker. Nevertheless …

Background The identification of protein biomarkers to guide treatment decisions regarding
adjuvant therapies for high-risk non-muscle-invasive bladder cancer (NMIBC) has been of …

Patients with muscle-invasive bladder cancer (MIBC) that underwent neoadjuvant
chemotherapy (NAC) prior to radical cystectomy (RC) show improved overall survival …